Video & Transcript Research : 'pharmaceutical'
Page 7 of 54
WY
Wyoming 2026 Regular Session
Senate Labor, Health & Social Services Committee, February 19, 2026
Labor, Health & Social Services
Transcript Highlights:
- Page three and four addresses the pharmaceutical care, allowing the pharmacist to decline participation
- :11.120>
four <00:03:11.360>addresses <00:03:11.680>the <00:03:11.920>pharmaceutical - and four addresses the pharmaceutical and four addresses the pharmaceutical care,<00:03:13.227><
Bills:
SF0121
Keywords:
pharmacy, collaborative care, healthcare, prescriptions, patient safety, Wyoming Pharmacy Act, 916, all
NH
New Hampshire 2026 Regular Session
Senate Health and Human Services (04/15/2026)
Health and Human Services
Transcript Highlights:
- EpiPens are pharmaceutical drugs.
- prescribing pharmaceutical drugs? prescribing pharmaceutical drugs?
- EpiPens are pharmaceutical drugs.
- <02:17:02.319>
like considered a pharmaceutical drug like considered a pharmaceutical drug - This is simply a disclosure bill to the patient. pharmaceutical companies spend hundreds pharmaceutical
FL
Transcript Highlights:
- I'm here representing today Otsuka Pharmaceuticals, one of our clients, who's worked directly with Chair
- I'm here representing today Outsica Pharmaceuticals, one of our clients, who's worked directly with Chair
- If you'll permit me, I'm just going to read a few notes provided through Otsuka Pharmaceuticals, and
- Otsuka Pharmaceuticals has supported initiatives similar to Senate Bill 264 across the country.
Summary:
The Senate Committee on Health Policy met with a quorum and heard five bills. SB 126, on prescription hearing aids, would remove Florida’s prohibition on mailing hearing aids when required tele-audiology testing and procedures are completed before sale. The sponsor said the bill would improve access, especially for people with travel or geographic barriers. The Florida Academy of Audiologists expressed support in concept but said it was still working with the sponsor on an amendment for consumer safety. The committee voted the bill favorably.
SB 152 would require hospitals and ambulatory surgical centers to adopt policies using smoke evacuation systems during certain surgical procedures. Supporters, including the Florida Nurses Association and several nurses, described surgical smoke as a workplace and patient safety hazard containing harmful chemicals, viruses, bacteria, and other contaminants, and said evacuation technology is available and already required in some settings. The committee voted the bill favorably. SB 264 would expand step-therapy exemptions for severe mental illness, including certain postpartum and pregnancy-related mental health conditions, so physicians would not have to require patients to fail preferred drugs in specified circumstances. Support came from Otsuka Pharmaceuticals, NAMI Florida, and several medical and pharmacy groups, who argued that delays in effective treatment can worsen crises and increase hospital and crisis-care costs. The committee voted the bill favorably.
SB 342 would create a public-records exemption for current and former AHCA employees and certain family information, citing threats and harassment directed at inspectors and regulators. President Gaetz said he generally opposes such exemptions but supported this one because the employees are not elected officials and face real safety risks. The committee voted the bill favorably. SB 294 would limit the Board of Pharmacy’s ability to add heart failure, coronary heart disease, and cardiac rhythm disorders to the list of chronic conditions eligible for collaborative pharmacy practice, keeping those conditions under direct physician management. The Florida Society of Thoracic and Cardiovascular Surgeons, Florida Medical Association, and the Florida chapter of the American College of Cardiology supported the bill, while the Florida Society of Health System Pharmacists opposed it. The committee voted the bill favorably. Senator Trumbull asked to be recorded in support of SB 126 and SB 152, and the meeting adjourned without further business.
TX
Transcript Highlights:
- So historically, many of our pharmaceuticals in this space relate to upregulating serotonin.
- Is it most pharmaceuticals? Didn't they originate from plant-based sources?
- Usually, pharmaceuticals are biologically inspired. Thank you, doctor.
- Why not let the federal government or the pharmaceutical industry do this?
- And so far as why don't, why won't the pharmaceuticals... industry develop this.
Bills:
HB 44, HB 2200, HB 1612, HB 2747, HB 2038, HB 3717, HB 1431, HB 3800, HB 3801, HB 3560, HB 3246
Keywords:
HB 44, Life of the Mother Act, abortion exceptions, medical emergency, reasonable medical judgment, pregnancy complications, maternal health, life-threatening condition, ectopic pregnancy, miscarriage, spontaneous abortion, fetal survival, Texas abortion law, abortion ban, physician liability, health care provider, disciplinary action, aiding and abetting, emergency abortion, obstetric care
Summary:
The meeting of the public health committee focused on the pressing issue of opioid addiction in Texas, with a particular emphasis on House Bill 3717. Chairman Harris detailed the bill's intent to fund a grant program for Ibogaine clinical trials, framing it as a critical response to the ongoing opioid crisis. He shared poignant testimonies highlighting the struggles of families and veterans battling addiction and mental health issues. The conversation underscored the necessity of innovative treatments, like Ibogaine, which showed promising results in studies for reducing symptoms of withdrawal and PTSD.
MA
Massachusetts 2025-2026 Regular Session
Senate Session (Full Formal with Calendar) Jun 21st, 2026 at 11:00 am
Massachusetts Senate Floor Meeting
Transcript Highlights:
- But given where we are today, given the reluctance of payers and providers and pharmaceutical companies
- The amendment excludes spending on pharmaceuticals, including medically administered drugs, from the
- Pharmaceutical costs reflect the price of a drug rather than a direct investment in primary care clinician
- It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate
- It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate
Summary:
The Senate considered a series of amendments to a primary care health care bill and also took up a separate literacy bill. Several amendments were withdrawn, including one on artificial intelligence in health care and others related to cost controls, direct primary care, and provider studies. The Senate adopted amendments on preserving access to treatment for serious mental illness, modernizing the definition of primary care, clarifying payment rates for community health centers, excluding pharmaceutical spending from primary care expenditure calculations, and strengthening health equity reporting. Other amendments on rate bands, alternative payment systems, private equity reporting, scope of practice, and ownership disclosure were rejected. The Senate then approved the Ways and Means amendment and ordered the primary care bill to a third reading.
The chamber also took up final passage of An Act Relative to Teachers Preparation and Student Literacy, with senators describing it as a long-awaited compromise focused on improving early reading outcomes. Supporters said the bill requires evidence-based K-3 literacy curricula, regular student screening and family notification, dyslexia screening protocols, professional development for teachers, and a free state-developed curriculum option. Senators emphasized the need to address declining third-grade reading proficiency and equity gaps. The bill passed to be enacted by a unanimous roll call and was sent to the Governor.
After the literacy bill, the Senate returned to the primary care bill, where senators again debated cost containment, innovation, and access. The final version included the adopted amendments and was passed to be engrossed by a roll call vote of 35-4. The Senate then adopted an adjournment order and recessed, adjourning in memory of Henry Thomas III, former Representative Ben Swan, and Mr. Dennis Frane.
FL
Transcript Highlights:
- , we are one of only two countries in the world that allow direct-to-consumer advertising for pharmaceuticals
- And you have people that are hearing these ads from the pharmaceutical companies claiming their vaccines
- are safe, incentivized. ...these ads from the pharmaceutical companies claiming their vaccines are safe
- We hear disclaimers at the end of general pharmaceutical commercials, sometimes all the potential side
- The pharmaceutical companies can educate doctors.
Keywords:
vaccine advertisement, manufacturer liability, harmful vaccine, healthcare, court action, smoking regulation, public health, vaping, marijuana, public places, Florida Statutes, alcohol distribution, tax deductions, extraordinary losses, warehouse breakage, regulatory compliance, veterinary, prescription, pharmacy, client rights
Summary:
The Committee on Regulated Industries considered several bills and took final action on each. SB 986, by Senator Gruters and presented by Senator Rodriguez, would prohibit smoking or vaping marijuana in public places and in certain indoor spaces; restaurant and lodging representatives supported adding marijuana and vaping to clean indoor air rules but asked to preserve designated smoking areas on private property, while cannabis advocates warned the bill was overly broad and could affect patients and property rights. The committee voted the bill favorably. SB 678, by Senator Mayfield, would restore statutory authority for DBPR to continue allowing alcohol distributors to deduct unsellable alcohol from monthly excise tax calculations; the committee adopted a strike-all amendment and reported the committee substitute favorably. SB 800, also by Senator Mayfield, increases penalties for repeated unlicensed engineering practice and creates an engineering student loan assistance program for engineers working for state agencies and water management districts; after adopting an amendment clarifying eligibility, the committee reported the bill favorably.
The committee then heard SB 408, by Senator Grall, which would create a Florida cause of action against vaccine manufacturers that advertise in the state, allowing injured individuals to sue in Florida courts. Supporters argued the bill would rebuild public trust and hold manufacturers accountable, while opponents from the Florida Justice Reform Institute, American Tort Reform Association, BIO, the U.S. Chamber Institute for Legal Reform, and several medical and business groups argued the field is largely preempted by federal law, that existing federal compensation programs already address vaccine injuries, and that the bill raises First Amendment and policy concerns. After debate focused on vaccine injury data, compensation rates, and liability, the committee voted SB 408 favorably.
The committee also considered SB 484 and SB 1118, both by Senator Avila, dealing with data centers. SB 484 would preserve local planning authority, bar nondisclosure agreements that prevent disclosure of potential data center development, require the PSC to set large-load tariff requirements so data centers pay their own costs, and limit consumptive use permits for large-scale data centers absent no harm to water resources and compliance with local zoning; supporters emphasized ratepayer protection and economic development, while some witnesses urged flexibility for behind-the-meter projects and confidentiality in negotiations. The bill was reported favorably. SB 1118 would create a time-limited public records exemption for county or municipal information about data center siting and protect proprietary business information; Senator Pizzo raised concerns about how the exemption would affect disclosure of competing projects and local officials’ ability to speak, but the sponsor said he would work on clarifying the language. The committee also passed SB 1050, by Senator Calatayud, which requires veterinarians to provide pet owners with written prescriptions and information about pharmacy choice while preserving veterinary judgment and emergency dispensing authority. The meeting concluded after all bills were reported favorably and members recorded additional votes on prior items.
CA
Transcript Highlights:
- Hospital costs have increased by more than 265% over the last five years, and pharmaceutical costs have
- Hospital costs have increased by more than 265% over the last five years, and pharmaceutical costs have
- Chair and members, Alison Ramey on behalf of the Pharmaceutical Care Management Association, in support
- Currently, pharmaceutical companies often offer coupons to privately insured patients to provide discounts
- Since pharmaceutical companies can change the coupon programs and patient eligibility rules for those
AR
Arkansas 2026 1st Special Session
ALC-GAME & FISH/STATE POLICE Jun 18th, 2026
ALC-GAME & FISH/STATE POLICE
Transcript Highlights:
- Before that, we were seeing a lot of your normal pharmaceutical drugs, and then most of the tablets..
- drug of the same family, but much more potent and not being, you know, not being created by a pharmaceutical
- And so for a little while, we saw the regular pharmaceuticals start to come back.
- public would not notice the slight little differences that might be there between those and normal pharmaceutical
Summary:
The committee met with representatives from the Arkansas State Crime Lab for what members said was likely the first appearance by the lab before this committee. Lab officials gave an overview of the new crime lab facility now under construction, saying it is on schedule, under budget, and expected to be completed by the end of July next year, with phased move-in beginning around August 1. They explained that the current building is over 40 years old and overcrowded, with caseloads having doubled over the past 20 years, and said the new facility will improve workflow, add morgue capacity, and allow new technologies and equipment to be brought online.
Members asked about staffing and recruitment, and the lab said recent pay changes and legislative support have made Arkansas more competitive for forensic specialists and medical examiners. Officials said vacancies have been reduced, a new deputy chief medical examiner has been hired, two more medical examiners are starting in August, and a new fellowship program has already attracted applicants. They also said the lab is prepared for the staffing needs of the new facility and that training periods remain long for many analyst positions.
The discussion also covered rapid DNA, CODIS, sexual assault kit processing, genetic genealogy, and overdose-related data sharing. The lab said rapid DNA is in final testing with pilot agencies in Faulkner and Saline counties and could go live by the end of July, which would make Arkansas among the first states to do so. Officials described CODIS as a key investigative tool, said DNA profiles are entered automatically when they qualify, and reported that the sexual assault kit backlog has been cleared with the lab now maintaining a 60-day turnaround. They also confirmed Arkansas uses a kit-tracking system, works with private labs such as Othram and Bode for genetic genealogy, and is developing an overdose dashboard to share toxicology and overdose data with public health and law enforcement partners. Members praised the lab’s progress and the committee adjourned after announcing an August site visit to Lake Conway and the dam project.
AR
Arkansas 2026 1st Special Session
ALC-GAME & FISH/STATE POLICE Jun 18th, 2026
ALC-GAME & FISH/STATE POLICE
Transcript Highlights:
- Before that, we were seeing a lot of your normal pharmaceutical drugs, and then most of the tablets..
- drug of the same family, but much more potent and not being, you know, not being created by a pharmaceutical
- And so for a little while, we saw the regular pharmaceuticals start to come back.
- public would not notice the slight little differences that might be there between those and normal pharmaceutical
KY
Kentucky 2026 Regular Session
House Legislative Session Day 16 (1-29-26)
Kentucky House Floor Meeting
Transcript Highlights:
- aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
- aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
- aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
- , beef, pork, and thoroughbred bourbon, beef, pork, and thoroughbred horses,<00:33:07.919>
pharmaceuticals - horses, pharmaceuticals, and machinery. horses, pharmaceuticals, and machinery.
Keywords:
Convene 00:00
Senate Message 04:45
Calendar/2nd Readings 05:20
Report of Committees 07:05
Orders of the Day 08:23
HB 214 08:33
HB 416 12:26
HB 281 16:20
HB 134 18:13
Motions, Petitions, and Communications 21:08
Introduction of New Bills and Resolutions 37:01
Recess for ConC/Rules Meeting 39:15
ConC/Rules Report 42:29
Floor Amendments 44:27
Correction to Introduction of New Bills and Resolutions 46:14
Adjournment 46:40, 958, all
Summary:
The House convened, heard an invocation focused on recovery from a recent storm, and recited the Pledge of Allegiance. A quorum was established with 94 members present, absent members were excused, and the rules were suspended to allow co-sponsorships and vote modifications. The journal was approved, and the clerk reported a Senate message transmitting Senate Joint Resolution 23 for concurrence.
The chamber then received second-reading reports on a wide range of bills covering pharmacist reimbursements, grooming a minor, local government liability, water fluoridation, solid waste, highway markings, fiduciary bonds, motor vehicle titles, hearing aid coverage, eating disorder coverage, public safety, pedestrians, cigar bars, backyard chickens, and county law libraries. Committee reports also advanced several bills, including measures on elections, local government, state-operated mental health facilities, prescription drugs, Alzheimer’s services, electric generating unit decommissioning costs, reemployment of retired police officers, and the Kentucky Communications Network Authority. Those favorable reports were treated as first readings and placed on the calendar.
The House passed several bills unanimously by roll call, including House Bill 214 on a program to help disabled veterans obtain and install home wheelchair ramps, House Bill 416 on educator preparation and early assessments, House Bill 281 on streamlining food donations by churches and nonprofits for shelters and disaster victims, and House Bill 134 on sexual assault nurse examiners, creating a statewide coordinator, registry, and regional access plan. In each case, sponsors explained the bills and members voiced support; floor amendment 1 to House Bill 416 was adopted before passage. Clinchers were applied after passage of the bills.
The House also adopted House Resolution 33 recognizing cancer patients, survivors, and families and designating January 29, 2026 as Suits and Sneakers Day, and adopted House Resolution 43 recognizing the economic and cultural partnership between Kentucky and Japan. Members offered additional citations honoring Newport Central Catholic High School and the YMCA, and the chamber observed a moment of silence for Boone County Sheriff Michael Helmig after a citation honoring his service and legacy. Announcements included committee meetings after adjournment, birthday wishes, and the introduction of numerous new bills and resolutions, including measures on kindergarten, bridges, revenue, retirement benefits, concealed deadly weapons, local taxes, motor vehicles, fiscal reporting, SNAP, families and children, vision testing, and a balanced budget amendment application.
KY
Kentucky 2025 Regular Session
House Standing Committee on Licensing, Occupations, & Administrative Regulations (3-5-25)
Transcript Highlights:
- We had a law, if you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical
- There are two steps they have to take: the medical board to get their licensing back, but the pharmaceutical
- We had a law, if you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical
- If you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical licensees
- There are two steps they have to take: the medical board to get their licensing back, but the pharmaceutical
Summary:
The committee first took up House Bill 90 / Senate Bill 17, a birth-related measure backed by the Kentucky Birth Coalition. Sponsors said the bill had been worked on for several years and described changes including a transfer agreement, insurance requirements, proximity to a hospital, informed consent, and accreditation/medical director standards that helped win neutral or non-opposition from the Hospital Association. The bill was reported favorably after a roll call vote with unanimous support.
The committee then heard Senate Bill 65, presented by Senator Steve West and Representative Derrick Lewis. They said the bill would make regulations found deficient through the committee review process null and void by statute, and would bar agencies from reissuing the same or similar language for up to a year. Supporters argued this was needed to hold agencies accountable because deficiency findings alone had not led to action. After questions about specific Medicaid behavioral health regulations and concerns about legislative overreach, the bill passed the committee on a roll call vote, with some members passing or explaining reservations.
Finally, the committee considered Senate Bill 84, with a House committee substitute. Sponsors said the substitute was intended to strengthen the bill and reflect the U.S. Supreme Court’s Loper Bright decision by ending Chevron deference and requiring courts, not agencies, to interpret law. Opponents, including Audrey Ernsberger and Katherine Hargraves, argued the bill would intrude on the judiciary, violate separation of powers, and could harm public health, environmental, and workplace protections. Committee members also raised concerns about whether the bill told courts what standard to use; sponsors responded that agencies could still present persuasive arguments, but courts should not defer to them. The committee substitute was adopted, and the bill then passed the committee on a roll call vote, with several members passing or expressing constitutional concerns.
MA
Massachusetts 2025-2026 Regular Session
Joint Committee on Public Health Jun 21st, 2026 at 10:00 am
Joint Committee on Public Health
Transcript Highlights:
- Vaccines, just like many other pharmaceutical products, are not one-size-fits-all.
- My career has been dedicated to diagnostics and pharmaceuticals.
- You have been hijacked by the big pharmaceutical companies.
- You worship pharmaceuticals like religion. It is insane. It is absolutely insane.
- Pharmaceutical companies, you have all become indoctrinated. It is shameful.
Summary:
The Joint Committee on Public Health held a hearing on several vaccination-related bills, including proposals to eliminate non-medical or religious exemptions for school immunizations (notably H. 2554 and S. 1557), a bill to require or improve reporting and administration of immunization data and exemptions (described as the Community Immunity Act, S. 1618), and H. 2431, which would prohibit COVID-19, mRNA, or gene-altering vaccine requirements. The committee also heard testimony on H. 2463, which would classify funeral directors as public health workers for vaccine-priority purposes during emergencies. The chair reviewed testimony rules and repeatedly asked speakers to keep comments orderly and brief so the committee could hear as many people as possible. No votes were taken during the hearing.
Testimony on H. 2554 and S. 1557 was sharply divided. Pediatricians, infectious disease specialists, public health advocates, and groups such as the Massachusetts Chapter of the American Academy of Pediatrics, Massachusetts Medical Society, March of Dimes, Massachusetts Families for Vaccines, and several parents supported eliminating religious exemptions, arguing that vaccination protects medically vulnerable children and adults, improves herd immunity, and helps prevent outbreaks of measles, pertussis, and other diseases. They cited local school data showing pockets of lower coverage and incomplete reporting, and several speakers referenced outbreaks in other states and the need for stronger, more consistent reporting and exemption management. Opponents argued the bills would infringe on religious freedom and parental rights, force families to choose between faith and education, and unfairly target a small number of families; some also said Massachusetts already has high vaccination rates and that the real issue is incomplete data or the gap population rather than religious exemptions.
H. 2431 drew testimony from supporters who said COVID-era mandates caused job losses, privacy concerns, and harm, and that the bill would prevent future requirements for COVID, mRNA, or gene-altering vaccines in schools, workplaces, and public settings. Supporters described personal experiences with alleged vaccine injury or mandate-related hardship. H. 2463 was supported by the Massachusetts Funeral Directors Association, which argued funeral directors work in infection-facing settings and should be eligible for vaccine priority during public health emergencies. The hearing featured extensive public testimony but no committee action beyond hearing the bills and taking questions from members.
CA
California 2025-2026 Regular Session
Assembly Health Committee Apr 22nd, 2025
Transcript Highlights:
- Everyone benefited from the 340B savings program, but as the pharmaceutical companies tightened access
- And when you have specialty pharmaceuticals, you have to get, like, special cancer drugs.
- There's a standard pharmaceutical fee for dispensing, but the 340B savings go directly back into your
- Alison Ramey here this evening on behalf of the Pharmaceutical Care Management Association.
- And the reality is that you have a market where you have big monopolies, pharmaceutical companies, who
Summary:
The Assembly Health Committee met on April 22 and took up a special order of bills focused largely on prior authorization and utilization management in health care. The chair framed the discussion as part of a broader legislative effort to reduce delays and barriers to care, especially in behavioral health, chronic disease management, cancer treatment, and rehabilitation services. AB 384 by Assembly Member Connolly would prohibit prior authorization for inpatient mental health or substance use emergency admissions and related physician care; supporters said it would prevent dangerous delays in crisis care, while insurers and health plans warned about fraud, abuse, and ambiguity around residential treatment facilities. The bill was moved on a due pass as amended motion and passed the committee on a party-line style vote, with Republicans largely absent or not voting.
The committee then heard AB 510 by Assembly Member Addis, which would require health plans, upon request, to provide a peer reviewer of the same or similar specialty when a treating provider appeals a prior authorization denial or modification. Supporters argued that specialty-matched review would make appeals fairer and more clinically informed; opponents said the requirement was too rigid and that timelines and electronic submission rules needed changes. After discussion about the need for timely, specialty-specific review, the bill was approved on a due pass as amended motion and placed on call. AB 539 by Assembly Member Schiavo would extend prior authorization approvals to one year or the duration of the physician’s prescribed treatment for chronic conditions; supporters cited repeated denials and treatment interruptions, while opponents raised concerns about overbreadth, fraud, and the need for shorter validity periods. The bill was also passed as amended and placed on call.
The committee next considered AB 669 by Assembly Member Haney, which would bar concurrent and retrospective review for the first 28 days of medically necessary substance use disorder treatment and limit prior authorization for related outpatient medications. The bill was presented with a powerful personal story from Ryan Matlock’s mother about her son’s death after an insurer cut off treatment early; supporters said the measure would keep patients in care long enough to stabilize, while opponents argued it would reduce oversight and could allow lower-quality or non-evidence-based care. The bill was moved on a due pass as amended motion and placed on call. Finally, AB 512 by Assembly Member Harabedian would shorten prior authorization response times to 24 hours for urgent requests and 48 hours for non-urgent requests; supporters said delays can worsen outcomes, while opponents warned the timelines were unrealistic and could increase administrative burdens and safety issues. The bill was approved as amended and placed on call. AB 574 by Assembly Member Mark Gonzalez was then heard; it would allow up to 12 medically necessary physical therapy sessions for a new episode of care without prior authorization, with supporters emphasizing stroke and neurological recovery and opponents warning of reduced oversight and unnecessary care. The transcript ends during testimony on AB 574, before final action is shown.
FL
Florida 2026 4th Special Session
January 21, 2026 - 04:00 PM
Transcript Highlights:
- FIRST UP IS MICHAEL POWER, PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION AN OPPONENTS OF THE BILL WISHING
- CHAIRMAN THANK YOU, MY NAME IS MICHAEL POWER WITH THE PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION, THE
- IT IS NOT MY INDUSTRY BUT IT FEELS TO ME AMERICANS ARE JUST GETTING SHAFTED BECAUSE PHARMACEUTICAL COMPANIES
- COMMEND PRESIDENT DONALD TRUMP AND THE TRUMP ADMINISTRATION FOR AT LEAST TRYING TO FORCE THE PHARMACEUTICAL
ND
North Dakota 2025-2026 Regular Session
Senate Industry and Business Apr 2nd, 2025 at 02:45 pm
Industry and Business
Transcript Highlights:
- There is no current pharmaceutical or pharmacy expertise within the insurance department, so we would
- There is no current pharmaceutical or pharmacy expertise within the insurance department that we would
- be creating a new division within the insurance department that we would be. pharmaceutical or pharmacy
- So this was an attempt to say, okay, the pharmaceutical industry will have some skin in the game with
Summary:
The Senate Committee on Industry and Business reconvened to work on House Bill 1584, which would create a new pharmacy benefit manager (PBM) regulatory structure within the Insurance Department. Insurance Commissioner John Godfrey and Deputy Commissioner John Arnold explained a revised set of amendments negotiated with Representative Casper and the North Dakota Pharmacists Association. They said the bill largely kept the House policy intact but added technical corrections, narrowed some references in Chapter 19-02, created a separate PBM licensing class, set a delayed effective date for licensing, and established emergency authority so the department could begin building the new division. They also described the proposal to fund the program through existing trust fund resources, PBM license fees, and a transfer of about $1.6 million from the prescription drug transparency program fund, while allowing the department flexibility to hire needed attorneys, pharmacists, and examiners.
A major point of discussion was Section 10, which would have required the Attorney General to represent and bear costs for lawsuits related to the bill. Chief Deputy Attorney General Claire Ness said the language was too broad and would go beyond normal constitutional defense work, potentially obligating her office to cover all lawsuits against the commissioner or state under the section. Representative Casper said the intent was only to avoid the Insurance Department having to seek emergency funding for litigation, and both he and department officials said they were open to removing the section or narrowing it. After further discussion, the committee agreed to remove Section 10 from the amendments.
The committee then voted 4-0 to adopt the amended amendment package, and then voted 4-0 to give House Bill 1584 a do pass recommendation as amended and refer it to Appropriations. Members noted the bill was still a work in progress, but said the revised version was intended to move the PBM regulation issue forward while continuing discussion in the appropriations process.
TX
Texas 89th Regular
Senate Committee on Health and Human Services Apr 15th, 2025
Health & Human Services
Transcript Highlights:
- You know, so for a pharmaceutical, for a potential therapeutic, let's say.
- Pharmaceutical companies are not looking at CPRIT as being the biggest investor with the biggest return
- But with a lot of pharmaceutical companies, that is not the magic moneymaker.
- And, again, not being greedy, but I think that when we look at the margins. of pharmaceutical drugs or
- Any other pharmaceutical substance is prescribed based on weight, size, and other individual factors.
Keywords:
pharmacist, vaccine administration, COVID-19, exclusive authority, healthcare, Medicaid, provider enrollment, credentialing, administrative burden, Texas Health and Human Services, senior retirement communities, emergency response, residential safety, contract provisions, health and safety regulations, medical staff privileges, hospital administration, healthcare regulation, Texas Health and Safety Code, consistency in privileges
KY
Kentucky 2025 Regular Session
House Standing Committee on Health Services (3-14-25) -Upon Recess of House - 6PM
Transcript Highlights:
- its place we are adding the provisions of Senate Bill 14, which prohibits discrimination by a pharmaceutical
- 02:51.480>
a prohibits the Discrimination uh by a prohibits the Discrimination uh by a pharmaceutical - that it was established but it um 90s that it was established but it um allows<00:05:47.080>
pharmaceutical - <00:05:47.800>
manufacturers <00:05:48.759>to allows pharmaceutical manufacturers to - allows pharmaceutical manufacturers to sell<00:05:50.240>
products <00:05:50.680>sell <
Keywords:
00:25 Call to Order/Roll Call
01:36 Discussion of 25RS SB 153
23:11 Roll Call Vote on 25RS SB 153
30:56 Adjournment, 958, all
Summary:
The House Standing Committee on Health Services met on March 14, 2025, and took up a committee substitute for Senate Bill 153. The substitute deleted the original bill language and replaced it with provisions from Senate Bill 14, aimed at prohibiting pharmaceutical manufacturers from discriminating against 340B covered entities and adding reporting requirements for those entities. The sponsor explained that the protections would sunset after one year, allowing lawmakers to review data by July 1, 2026, and that Kentucky would continue to follow any future federal changes to the 340B program.
Members asked several questions about the scope of the reporting, including what “total operating cost” means, how duplicate discounts are prevented, whether the reporting applies only to hospitals and not federally qualified health centers, and who would receive the data. The sponsor said the reporting is intended to help the Cabinet for Health and Family Services and the Office of Health Data Analytics at LRC assess how the program is working, including charity care and community benefits, while preserving protections for rural hospitals and allowing them to continue using contract pharmacies. A representative from LRC confirmed the data would come to the General Assembly through the Office of Health Data Analytics.
The committee expressed mixed views about the balance between transparency and potential burdens on hospitals, especially rural facilities. Several members said they were supportive but had reservations about the reporting requirements and the sunset structure, while others noted concerns about unintended consequences and the possibility of changes on the House floor. The committee ultimately adopted the committee substitute, approved a title amendment, and reported Senate Bill 153 with House Committee Substitute 2 favorably. The meeting then adjourned.
CA
California 2025-2026 Regular Session
Assembly Budget Subcommittee No. 1 on Health Feb 24th, 2025
Transcript Highlights:
- Sure, so you may have heard about a bankruptcy of the various pharmaceutical companies involved in the
- I'm sorry, so there was an opioid settlement where we were holding the pharmaceutical companies accountable
- Pharmaceutical companies.
- Is it because pharmaceuticals are going up? Can you just explain a little bit more? Sure.
- facility, which was a hospital, and dispensed over 12,500 over-the-counter medications and 10,000 pharmaceuticals
MN
Minnesota 2025-2026 Regular Session
Conference Committee on H.F. 4188 - Omnibus Commerce and Consumer Protection - Part 2 - 05/12/26
Transcript Highlights:
- First, we are concerned with the language regarding pharmaceutical advertising.
- is clear that the intent of these provisions is intended to prescribe the behavior of pharmaceutical
- Enforcement of these provisions should therefore be targeted only at pharmaceutical companies.
- As a practical matter, compliance responsibility should rest solely with pharmaceutical companies who
- Again, if the intent of the bill is to prescribe pharmaceutical ads, then the bill should prevent the
Summary:
The committee heard public testimony on a health insurance/home care nursing provision and on other consumer protection items. Nick Keis and Emily Walters, both parents of medically complex children, testified that commercial health plans had recently begun capping home care nursing as if it were intermittent home health visits, which they said was contrary to Minnesota law and legislative intent dating to 2010. They described severe impacts on their families, including hospitalizations, loss of nursing coverage, strain on waiver budgets, and the risk of children being forced out of the home and into institutions. Representative Bierman echoed that the bill was a straightforward clarification of existing law, not a new mandate or added cost, and a staff member later cited the statutory definition of home care nursing as ongoing, continuous nursing services that cannot be met through intermittent or visit-based care. The committee also discussed the practical difference between home health visits and private duty/home care nursing, with testimony emphasizing that the latter is medically necessary, assessed, and not unlimited in practice.
Laura Sales of the Minnesota Attorney General’s Office testified on changes to the Consumer Protection Restitution Fund (CIPRA). She said the fund has begun distributing restitution, starting with consumers harmed by the closure of Woodbury Dental Arts, but that current statutory language limits the office’s flexibility to prorate payments. She asked for an amendment allowing the AGO to distribute available funds more equitably so more eligible consumers can receive some payment, rather than requiring full payment to the oldest claims first.
Annette Meeks, representing Citizens Against Gambling Expansion, testified in support of banning sweepstakes gambling in the Commerce Committee omnibus report. She argued that online sweepstakes casinos are an illegal gray-market form of gambling, cited rapid growth and billions in revenue, and said other states have acted through enforcement and legislation to stop them. She urged the committee to include language from Senate File 4474 to clarify state law and prohibit sweepstakes gambling. No votes were taken in the portion of the meeting shown; members mainly asked questions and received testimony.
MN
Minnesota 2025-2026 Regular Session
Committee on State and Local Government - 03/12/26
State and Local Government
Transcript Highlights:
- approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
- approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
- approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
- approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
- approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical